Predicting cancer recurrence and treatment benefits for early-stage lung cancer patients
Official title: Accurate prognosis and prediction of clinical benefits of adjuvant therapy for early-stage non-small cell lung cancer
Funded at Sostos LLC · NIH-10821728 · Data updated 2026-11-12
This study is working on a new test that looks at 7 specific genes to help predict if early-stage lung cancer might come back after surgery and to see if extra chemotherapy could be helpful for patients who have had surgery for stage 1 non-small cell lung cancer.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sostos LLC NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $400,000 |
| NIH project number | 1R43CA281430-01A1 |
| Project ID | NIH-10821728 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have undergone surgical resection for stage 1 non-small cell lung cancer without high-risk features.
✕Less likely to help
Patients with advanced-stage lung cancer or those who have not undergone surgical resection may not benefit from this research.
What this research studies
This research focuses on developing a new test that uses a 7-gene assay to predict the likelihood of cancer recurrence and the effectiveness of chemotherapy for patients with early-stage non-small cell lung cancer (NSCLC) who have had surgery. By utilizing advanced artificial intelligence methods and analyzing genetic information from patients, the study aims to provide more accurate prognoses and treatment recommendations. Patients who have undergone surgery for stage 1 NSCLC without high-risk features will be the primary focus, as the test seeks to identify those at higher risk for recurrence and determine the potential benefits of additional chemotherapy.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for early-stage lung cancer patients, improving their chances of survival and quality of life.
How similar studies have gone: Previous studies have shown promising results using similar genetic and AI-based approaches to predict cancer outcomes, indicating potential for success in this research.
Where this research is happening
-
Sostos LLC
Morgantown, United States Active
Researchers
- Principal investigator: Ye, Qing — Sostos LLC
- Study coordinator: Ye, Qing
Related research
Other NIH-funded projects on the same topics.
-
Blood and airway microbe and gene tests to find and predict early non-small cell lung cancer
This project looks for microbial and host gene signals in blood and airway samples to help spot early non-small cell lung cancer and predict who might have the cancer come back.
-
Developing biomarkers to detect and predict outcomes of early-stage lung cancer
This study is looking for helpful signs in blood and lung samples that can spot non-small cell lung cancer early and tell if a lung nodule is cancerous or not, which could lead to better treatment for patients with early-stage lung cancer.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.